|Day Low/High||82.51 / 84.12|
|52 Wk Low/High||58.67 / 92.84|
From a market perspective, there are going to be plenty of winners lining up for their share of the riches.
The elevator maker's charts are pushing the right buttons.
This week will tax your brain. Your ability to focus on what really matters will be tested.
The shares have worked higher over the past 12 months.
Getting dizzy looking down from here? Then look up, because we may just be getting started on this market.
So far, for the season, the blended rate of earnings growth for the first quarter now stands at an incredible 33.8%.
This is how you enforce portfolio allocation discipline upon yourself.
I'd anticipate further sideways price action until we see good strength in the OBV line.
Let's not kid ourselves that there is any longer some kind of relationship between price and value. Or fact and truth.
Many CEOs disagreed with a number of Trump's positions and are looking forward to a new, more predictable regime.
Here's how I'd play the stock with third-quarter results set for after the close Monday.
There is no stimulus deadline. There is no deal. There are only the games people play.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
Let's check the charts and indicators.
Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.